Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin-Reference-Cited by-同舟云学术

Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin

Published:2019-11-05 Issue:1 Volume:21 Page:121-130
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Hayashi Tomoko¹,Murayama Hiroki¹,Shinfuku Yohei²,Taniguchi Tomoko²,Tsumiyama Isao³,Oyama Naotsugu¹

Affiliation:

1. Medical Division, Novartis Pharma K.K., Tokyo, Japan

2. Regulatory Office Japan, Novartis Pharma K.K., Tokyo, Japan

3. Japan Development, Novartis Pharma K.K., Tokyo, Japan

Funder

Novartis Pharma K.K.

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2019.1685500

Reference23 articles.

1. Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

2. The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose

3. Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

4. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study

5. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isolation and Quantification of Palmatine from Fibraurea tinctoria Lour: In Vitro Antioxidant Activity and In Silico Antidiabetic Activity Evaluation;Drug Design, Development and Therapy;2024-08

2. Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective;Clinical Medicine Insights: Endocrinology and Diabetes;2024-01

3. Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition;Acta Pharmaceutica Sinica B;2022-11

4. Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus;Journal of Clinical Medicine Research;2021-06

5. Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management;Bioinformation;2021-03-31